Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines

Executive Summary

Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.

You may also be interested in...



Shaw Leaves Lilly To Helm Gilead’s Kite

After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.

The Outcomes-Based Reimbursement Experiment

US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.

Glass Ceiling Cracked; Pharma Forges Path To Gender Equality By 2040?

One woman CEO is an improvement, but at this rate gender equality won't arrive before immuno-oncology goes generic.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel